HHS turns to venture capital for next pandemic To view this email as a web page,
click here | | Webinar: Accelerating NASH Clinical Trials Tuesday, June 15 | 10am ET / 7am PT Join industry leaders for a webinar dedicated to overcoming key challenges presented in NASH drug development. We’ll explore key considerations for liver biopsy collection and interpretation, emerging non-invasive biomarkers, and the connection between clinical practice and drug development. Register now. |
Abbott takes an ax to sales forecast as COVID testing dries up faster than expected HHS launches $50M venture capital partnership to develop tech for pandemic response Government relief, summer volume spikes kept primary physicians afloat in 2020: MGMA report Pandemic's spotlight on pharma resurfaces longstanding contradictions: report UPDATED Coronavirus tracker: Employers' vaccine requirements legal, federal commission says COVID-19 tracker: WHO backs Sinovac vaccine; Denmark reconsiders AstraZeneca, J&J vaccine hold Featured Story | By Conor Hale The peak for COVID-19 testing may have thoroughly passed—judging by Abbott's new sales projections, at least. The testing giant now projects steeper-than-expected declines in diagnostic testing as vaccination rates climb, and it's not only slashed its sales forecast by as much as $2 billion, but also cut its spending plans for the rest of the year. read more |
| |
|---|
|
Top Stories By Heather Landi The federal government wants to tap into venture capital approaches to help bring to market breakthrough technologies in preparation for the next pandemic. BARDA Ventures, the venture arm of the Biomedical Advanced Research and Development Authority, is partnering with a nonprofit to invest a minimum of $50 million over five years with the potential for up to $500 million over 10 years to commercialize new tech and medical products. read more By Jacqueline Renfrow Despite the pandemic, physician compensation remained steady in 2020, with a modest increase in compensation for primary care physicians and a slight increase for specialty physicians. read more By Beth Snyder Bulik Thanks to the pandemic, everyone is looking at the pharma industry again—but what many are seeing are the same old contradictions. Along with new appreciation for the industry and its quick pandemic response comes a less favorable spotlight on longstanding problems around pricing, access and the complex U.S. healthcare system, a new report finds. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The World Health Organization authorized the vaccine from China's Sinovac, paving the way for its deployment in poorer nations. Denmark is reconsidering its decision to exclude the shots from Johnson & Johnson & AstraZeneca in its vaccination program. And more headlines. read more |
|
